Shanghai Institute Of Biological Products

This early-stage trial tests a new influenza vaccine in 120 adults aged 60 and older. Participants receive either a high-dose vaccine, a standard-dose vaccine, or a placebo. The study focuses on safety and how well the vaccine triggers an immune response, with the goal of develop…

This study tests a new recombinant shingles vaccine in healthy adults aged 40 and above. Researchers will give two doses and monitor for side effects and immune response. The trial involves 645 participants and compares the new vaccine to an existing one (Shingrix) and placebo.

This early-stage trial is testing a new vaccine against monkeypox in 120 healthy adults aged 18 and older. Participants will receive two doses of either a low or high dose of the MVA strain live vaccine, or a placebo. The study aims to check if the vaccine is safe and whether it …

This phase II trial tests a new drug called SIBP-03, given together with cetuximab, for people with advanced head and neck cancer that has returned or spread. The study will enroll 81 adults who have already tried immunotherapy and platinum chemotherapy. The goal is to see if the…

This early-stage study tests a new injectable drug called peguricase, given together with methotrexate, in 36 adults with gout that standard treatments cannot control. The main goals are to check safety, how the drug moves through the body, and whether it helps lower uric acid. P…

This early-phase trial is testing a new drug, SIBP-A19, in 156 people with advanced solid tumors who have no other standard treatment options. The main goals are to check the drug's safety, find the best dose, and look for early signs that it might shrink tumors. The drug is give…

This early-phase trial tests a new drug called SIBP-A10 in 160 adults with advanced tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will receive the drug and be monitored for s…

This early-stage trial tests a new drug called SIBP-A17 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER2 found on some cancer cells. The study aims to find the safest dose and understand how the drug works…

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants will re…

This early-stage study tests a new drug called SIBP-A18 in 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug and a…

This early-stage trial is testing an experimental drug called SIBP-A16 in 140 healthy adults aged 18 to 45. The goal is to see if it is safe and how the body handles it. Participants receive a single injection of the drug, a placebo, or an existing RSV antibody. The study does no…